These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 23733394)

  • 21. Dopamine affects the stability, hydration, and packing of protofibrils and fibrils of the wild type and variants of alpha-synuclein.
    Follmer C; Romão L; Einsiedler CM; Porto TC; Lara FA; Moncores M; Weissmüller G; Lashuel HA; Lansbury P; Neto VM; Silva JL; Foguel D
    Biochemistry; 2007 Jan; 46(2):472-82. PubMed ID: 17209557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective detection, quantification, and subcellular location of alpha-synuclein aggregates with a protein aggregate filtration assay.
    Kramer ML; Behrens C; Schulz-Schaeffer WJ
    Biotechniques; 2008 Mar; 44(3):403-11. PubMed ID: 18361794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of exogenous alpha-synuclein on stimulated dopamine overflow in dorsal striatum.
    Pelkonen A; Kallunki P; Yavich L
    Neurosci Lett; 2013 Oct; 554():141-5. PubMed ID: 24021803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
    Maingay M; Romero-Ramos M; Carta M; Kirik D
    Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nasal inoculation with α-synuclein aggregates evokes rigidity, locomotor deficits and immunity to such misfolded species as well as dopamine.
    Gruden MA; Davidova TV; Yanamandra K; Kucheryanu VG; Morozova-Roche LA; Sherstnev VV; Sewell RD
    Behav Brain Res; 2013 Apr; 243():205-12. PubMed ID: 23333843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models.
    Sato H; Kato T; Arawaka S
    Rev Neurosci; 2013; 24(2):115-23. PubMed ID: 23314528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Studies of the denaturation patterns of bovine alpha-crystallin using an ionic denaturant, guanidine hydrochloride and a non-ionic denaturant, urea.
    Doss-Pepe EW; Carew EL; Koretz JF
    Exp Eye Res; 1998 Dec; 67(6):657-79. PubMed ID: 9990331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
    El-Agnaf OM; Paleologou KE; Greer B; Abogrein AM; King JE; Salem SA; Fullwood NJ; Benson FE; Hewitt R; Ford KJ; Martin FL; Harriott P; Cookson MR; Allsop D
    FASEB J; 2004 Aug; 18(11):1315-7. PubMed ID: 15180968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Off-pathway α-synuclein oligomers seem to alter α-synuclein turnover in a cell model but lack seeding capability in vivo.
    Fagerqvist T; Näsström T; Ihse E; Lindström V; Sahlin C; Tucker SM; Kasaryan A; Karlsson M; Nikolajeff F; Schell H; Outeiro TF; Kahle PJ; Lannfelt L; Ingelsson M; Bergström J
    Amyloid; 2013 Dec; 20(4):233-44. PubMed ID: 24053224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
    Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
    Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by alpha-synuclein.
    Park SS; Schulz EM; Lee D
    Eur J Neurosci; 2007 Dec; 26(11):3104-12. PubMed ID: 18005066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of fibrillation process of alpha-synuclein at the initial stage.
    Tashiro M; Kojima M; Kihara H; Kasai K; Kamiyoshihara T; Uéda K; Shimotakahara S
    Biochem Biophys Res Commun; 2008 May; 369(3):910-4. PubMed ID: 18329380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The interplay between lipids and dopamine on α-synuclein oligomerization and membrane binding.
    Pham CL; Cappai R
    Biosci Rep; 2013 Oct; 33(5):. PubMed ID: 24066973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteomic analysis of dopamine and α-synuclein interplay in a cellular model of Parkinson's disease pathogenesis.
    Alberio T; Bossi AM; Milli A; Parma E; Gariboldi MB; Tosi G; Lopiano L; Fasano M
    FEBS J; 2010 Dec; 277(23):4909-19. PubMed ID: 20977677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathological roles of α-synuclein in neurological disorders.
    Vekrellis K; Xilouri M; Emmanouilidou E; Rideout HJ; Stefanis L
    Lancet Neurol; 2011 Nov; 10(11):1015-25. PubMed ID: 22014436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective loss of dopaminergic neurons and formation of Lewy body-like aggregations in alpha-synuclein transgenic fly neuronal cultures.
    Park SS; Lee D
    Eur J Neurosci; 2006 Jun; 23(11):2908-14. PubMed ID: 16819979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Redox activity of α-synuclein-Cu is silenced by Zn₇-metallothionein-3.
    Meloni G; Vašák M
    Free Radic Biol Med; 2011 Jun; 50(11):1471-9. PubMed ID: 21320589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Caenorhabditis elegans as a model system for identifying effectors of α-synuclein misfolding and dopaminergic cell death associated with Parkinson's disease.
    Harrington AJ; Knight AL; Caldwell GA; Caldwell KA
    Methods; 2011 Mar; 53(3):220-5. PubMed ID: 21195766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease.
    Zhou J; Broe M; Huang Y; Anderson JP; Gai WP; Milward EA; Porritt M; Howells D; Hughes AJ; Wang X; Halliday GM
    Acta Neuropathol; 2011 Jun; 121(6):695-704. PubMed ID: 21400129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation.
    Bellucci A; Collo G; Sarnico I; Battistin L; Missale C; Spano P
    J Neurochem; 2008 Jul; 106(2):560-77. PubMed ID: 18410503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.